تداخلات فليكاينيد

Drug Class Drugs within class that are contraindicated with REYATAZ Alpha 1-adrenoreceptor antagonist Alfuzosin Anticonvulsants Carbamazepine, phenobarbital, phenytoin Antiarrhythmics Amiodarone (with ritonavir), quinidine (with ritonavir) Antimycobacterials Rifampin Antineoplastics Apalutamide, encorafenib, irinotecan, ivosidenib Antipsychotics Lurasidone (with… (نشرة أتازانافير، موانع الاستعمال)

Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication. (نشرة فليكاينيد، تحذير مؤطر)

Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication. (نشرة فليكاينيد، تحذير مؤطر)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (نشرة أزيثرومايسين، التحذيرات والاحتياطات)

Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication. (نشرة فليكاينيد، تحذير مؤطر)

Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication. (نشرة فليكاينيد، تحذير مؤطر)

The use of SAPHRIS should be avoided in combination with other drugs known to prolong QTc including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and antibiotics (e.g., gatifloxacin, moxifloxacin). (نشرة أسينابين، التحذيرات والاحتياطات)

Concomitant use of COMPLERA with drugs with a known risk to prolong the QTc interval of the electrocardiogram may increase the risk of Torsade de Pointes. (نشرة إمتريسيتابين وريلبيفيرين وتينوفوفير، التحذيرات والاحتياطات)

Reserve the combination of amiodarone with other antiarrhythmic therapies that prolong the QTc to patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent. (نشرة أميودارون، التحذيرات والاحتياطات)

Avoid coadministration of oxaliplatin injection with medicinal products with a known potential to prolong the QT interval. (نشرة أوكساليبلاتين، التداخلات الدوائية)

Antiarrhythmics Disopyramide Dofetilide Dronedarone Quinidine Contraindicated during and 2 weeks after TOLSURA treatment. (نشرة إيتراكونازول، التداخلات الدوائية)

Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (نشرة إيفابرادين، التحذيرات والاحتياطات)

Avoid the use of FANAPT in combination with any other drugs that prolong the QT interval [see Warnings and Precautions (5.3) ] . (نشرة إيلوبيريدون، التداخلات الدوائية)

Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (نشرة بازوبانيب، التداخلات الدوائية)

…asymptomatic non-life-threatening ventricular arrhythmias who had a myocardial infarction more than 6 days but less than 2 years previously, an increased rate of death or reversed cardiac arrest rate (7.7%; 56/730) was seen in patients treated with encainide or flecainide (Class IC antiarrhythmics) compared with that seen in patients assigned to placebo (3 %; 22/725). (نشرة بروبافينون، تحذير مؤطر)

Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication. (نشرة فليكاينيد، تحذير مؤطر)

…patients with asymptomatic non-life-threatening ventricular arrhythmias who had a myocardial infarction more than six days but less than two years previously, an excessive mortality or non-fatal cardiac arrest rate (7.7%) was seen in patients treated with encainide or flecainide compared with that seen in patients assigned to matched placebo-treated group (3.0%). (نشرة بروكاييناميد، تحذير مؤطر)

Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication. (نشرة فليكاينيد، تحذير مؤطر)

Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication. (نشرة فليكاينيد، تحذير مؤطر)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (نشرة بيتوليسانت، التحذيرات والاحتياطات)

Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication. (نشرة فليكاينيد، تحذير مؤطر)

Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication. (نشرة فليكاينيد، تحذير مؤطر)

Because pimozide prolongs the QT interval of the electrocardiogram it is contraindicated in patients with congenital long QT syndrome, patients with a history of cardiac arrhythmias, patients taking other drugs which prolong the QT interval of the electrocardiogram or patients with known hypokalemia or hypomagnesemia (see also PRECAUTIONS - DRUG INTERACTIONS ). (نشرة بيموزيد، موانع الاستعمال)

Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication. (نشرة فليكاينيد، تحذير مؤطر)

Certain conditions may increase the risk for torsade de pointes or sudden death such as (1) bradycardia; (2) hypokalemia or hypomagnesemia; (3) concomitant use of other drugs that prolong the QTc interval; and (4) presence of congenital prolongation of the QT interval [see Warnings and Precautions ( 5.8 ), Clinical Pharmacology (12.2) ]. (نشرة تيترابينازين، التداخلات الدوائية)

Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication. (نشرة فليكاينيد، تحذير مؤطر)

CONTRAINDICATIONS Thioridazine hydrochloride tablet use should be avoided in combination with other drugs that are known to prolong the QTc interval and in patients with congenital long QT syndrome or a history of cardiac arrhythmias. (نشرة ثيوريدازين، موانع الاستعمال)

Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication. (نشرة فليكاينيد، تحذير مؤطر)

Use with Drugs that Prolong QT Interval and Antiarrhythmic Agents The use of dofetilide in conjunction with other drugs that prolong the QT interval has not been studied and is not recommended. (نشرة دوفيتيليد، التحذيرات)

Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication. (نشرة فليكاينيد، تحذير مؤطر)

…asymptomatic non-life-threatening ventricular arrhythmias who had had a myocardial infarction more than 6 days but less than 2 years previously, an excessive mortality or non-fatal cardiac arrest rate (7.7%) was seen in patients treated with encainide or flecainide compared with that seen in patients assigned to carefully matched placebo-treated groups (3.0%). (نشرة ديسوبيراميد، تحذير مؤطر)

WARNING: DRUG-DRUG INTERACTIONS LEADING TO POTENTIALLY SERIOUS AND/OR LIFE THREATENING REACTIONS Co-administration of NORVIR with several classes of drugs including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations may result in potentially serious and/or life-threatening adverse events due to possible effects of NORVIR on the hepatic metabolism… (نشرة ريتونافير، تحذير مؤطر)

…drugs, ziprasidone is contraindicated: • in patients with a known history of QT prolongation (including congenital long QT syndrome) • in patients with recent acute myocardial infarction • in patients with uncompensated heart failure Pharmacokinetic/pharmacodynamic studies between ziprasidone and other drugs that prolong the QT interval have not been performed. (نشرة زيبراسيدون، موانع الاستعمال)

Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication. (نشرة فليكاينيد، تحذير مؤطر)

Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval. (نشرة سيبروفلوكساسين، التحذيرات والاحتياطات)

Avoid the concomitant use of drugs known to prolong the QTc interval. (نشرة سيرترالين، التداخلات الدوائية)

QT Prolongation : Patients with congenital QT syndrome or taking class IA or III antiarrhythmics should avoid using vardenafil hydrochloride tablets. (نشرة فاردينافيل، التحذيرات والاحتياطات)

Coadministration of other drugs known to prolong the QT interval and which are metabolized via the enzyme CYP3A4 such as erythromycin, pimozide, and quinidine are contraindicated in patients receiving fluconazole. (نشرة فلوكونازول، موانع الاستعمال)

Fosamprenavir calcium is contraindicated when coadministered with the following drugs: Alpha 1-adrenoreceptor antagonist: Alfuzosin Antiarrhythmics: Flecainide (with ritonavir ), propafenone (with ritonavir ) Antimycobacterial: Rifampin Antipsychotic: Lurasidone (with ritonavir ), pimozide Ergot derivatives: Dihydroergotamine, ergonovine, ergotamine, methylergonovine… (نشرة فوسامبرينافير، موانع الاستعمال)

Avoid co-administration of CONTEPO with drugs known to prolong the QT interval. (نشرة فوسفومايسين، التداخلات الدوائية)

(See DOSAGE and ADMINISTRATION. ) Because of the risk of QT prolongation and the potential for torsades de pointes, the use of FOSCAVIR should be avoided in combination with agents known to prolong the QT interval including Class IA (e.g., quinidine or procainamide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents, phenothiazines, tricyclic… (نشرة فوسكارنت، التداخلات الدوائية)

Avoid concomitant use of VEPPANU with strong CYP3A inhibitors or drugs known to prolong the QTc interval. (نشرة فيبديغيسترانت، التحذيرات والاحتياطات)

Drugs that Prolong the QT Interval : Avoid concomitant use. (نشرة فينوباربيتال، التداخلات الدوائية)

Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication. (نشرة فليكاينيد، تحذير مؤطر)

QT Prolongation : Avoid clarithromycin tablets in patients with known QT prolongation or receiving drugs known to prolong the QT interval, ventricular arrhythmia ( torsades de pointes ), hypokalemia/hypomagnesemia, significant bradycardia, or taking Class IA or III antiarrhythmics ( 5.2 ) (نشرة كلاريثرومايسين، التحذيرات والاحتياطات)

Proarrhythmic effects Like many other drugs (including all other Class Ia antiarrhythmics), quinidine prolongs the QT c interval, and this can lead to torsades de pointes , a life-threatening ventricular arrhythmia (see OVERDOSAGE ). (نشرة كينيدين، التحذيرات)

These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (نشرة لاباتينيب، التحذيرات والاحتياطات)

Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication. (نشرة فليكاينيد، تحذير مؤطر)

Alpha 1- Adrenoreceptor Antagonist: alfuzosin Antianginal: ranolazine Antiarrhythmic: dronedarone Anti-gout: colchicine Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine GI Motility Agent: cisapride Hepatitis C direct acting antiviral: elbasvir/grazoprevir HMG-CoA Reductase Inhibitors: lovastatin, simvastatin… (نشرة لوبينافير وريتونافير، موانع الاستعمال)

Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval ( 5.11 , 8.5 ) (نشرة ليفوفلوكساسين، التحذيرات والاحتياطات)

Therefore, moxifloxacin should be avoided with Class IA and Class III antiarrhythmics [see Warnings and Precautions ( 5.6 ), Nonclinical Toxicology ( 13.2 ), and Patient Counseling Information ( 17 )]. (نشرة موكسيفلوكساسين، التداخلات الدوائية)

Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication. (نشرة فليكاينيد، تحذير مؤطر)

Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication. (نشرة فليكاينيد، تحذير مؤطر)

Examples diazepam, alprazolam, alcohol Drugs that Prolong QTc Interval Clinical Impact The concomitant use of other drugs which prolong the QTc interval with REMERON/REMERONSolTab, increase the risk of QT prolongation and/or ventricular arrhythmias (e.g., Torsades de Pointes). (نشرة ميرتازابين، التداخلات الدوائية)

…asymptomatic non-life-threatening ventricular arrhythmias who had a myocardial infarction more than six days but less than two years previously, an excessive mortality or non-fatal cardiac arrest rate (7.7%) was seen in patients treated with encainide or flecainide compared with that seen in patients assigned to carefully matched placebo-treated groups (3.0%). (نشرة ميكسيليتين، تحذير مؤطر)

Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication. (نشرة فليكاينيد، تحذير مؤطر)

Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication. (نشرة فليكاينيد، تحذير مؤطر)

…concentrations are associated with serious and/or life-threatening reactions [see Drug Interactions (7.3) ] : • Alpha 1-adrenoreceptor antagonist: alfuzosin • Antianginal: ranolazine • Antiarrhythmic: amiodarone, dronedarone, flecainide, propafenone, quinidine • Anti-gout: colchicine (in patients with renal and/or hepatic impairment [see Table 2 , Drug Interactions… (نشرة نيرماتريلفير وريتونافير، موانع الاستعمال)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (نشرة هيدروكسي كلوروكين، التحذيرات والاحتياطات)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (نشرة فليكاينيد، التداخلات الدوائية)

MAO inhibitors, tricyclic antidepressants and drugs that prolong the QTc interval may potentiate effect on the cardiovascular system. (نشرة أرفورموتيرول، التداخلات الدوائية)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (نشرة فليكاينيد، التداخلات الدوائية)

Erythromycin should be avoided in patients with known prolongation of the QT interval, patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, and in patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents. (نشرة إريثرومايسين، التحذيرات)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (نشرة فليكاينيد، التداخلات الدوائية)

Antiarrhythmics: e.g., amiodarone bepridil digoxin Indicates that a drug-drug interaction trial was conducted. disopyramide flecainide systemic lidocaine mexiletine propafenone quinidine ↑ antiarrhythmics ↑ digoxin Caution is warranted and therapeutic concentration monitoring, if available, is recommended for antiarrhythmics when coadministered with GENVOYA. (نشرة إلفيتيغرافير وكوبيسيستات وإمتريسيتابين وتينوفوفير، التداخلات الدوائية)

Ofloxacin should be avoided in patients with known prolongation of the QT interval, patients with uncorrected hypokalemia, and patients receiving Class IA (quinidine, procainamide), or Class III (amiodarone, sotalol) antiarrhythmic agents. (نشرة أوفلوكساسين، الاحتياطات)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (نشرة فليكاينيد، التداخلات الدوائية)

Use olanzapine and fluoxetine capsules with caution in combination with other drugs that prolong the QT interval ( 4.2 , 5.20 , 7.7 , 7.8 ) 7.1 Monoamine Oxidase Inhibitors (MAOIs) [See Dosage and Administration ( 2.4 , 2.5 ), Contraindications ( 4.1 ), and Warnings and Precautions ( 5.6 )] . (نشرة أولانزابين وفلوكسيتين، التداخلات الدوائية)

…like other beta 2 -agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval or within 2 weeks of discontinuation of such agents, because the effect of adrenergic agonists on the cardiovascular system may be potentiated by these agents. (نشرة أوميكليدينيوم وفيلانتيرول، التداخلات الدوائية)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (نشرة فليكاينيد، التداخلات الدوائية)

QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. (نشرة إيريبولين، التحذيرات والاحتياطات)

Monitor QT interval when administering FORANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (نشرة إيزوفلوران، التحذيرات والاحتياطات)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (نشرة فليكاينيد، التداخلات الدوائية)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (نشرة فليكاينيد، التداخلات الدوائية)

Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (نشرة باسيريوتيد، التداخلات الدوائية)

…combination with other drugs that are known to prolong QTc including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (e.g., chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to prolong the QTc interval. (نشرة باليبيريدون، التحذيرات والاحتياطات)

QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between Primaquine phosphate Tablets and other drugs that effect cardiac conduction is unknown. (نشرة بريماكين، التداخلات الدوائية)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (نشرة فليكاينيد، التداخلات الدوائية)

Drugs Metabolized by CYP2D6: Bupropion inhibits CYP2D6 and can increase concentrations of: antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). (نشرة بوبروبيون، التداخلات الدوائية)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (نشرة بوبرينورفين، التحذيرات والاحتياطات)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (نشرة بوبرينورفين ونالوكسون، التحذيرات والاحتياطات)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (نشرة فليكاينيد، التداخلات الدوائية)

Anti-Arrhythmic Drugs, QT Prolonging Drugs, Drugs that may Decrease Heart Rate PONVORY has not been studied in patients taking QT prolonging drugs. (نشرة بونيسيمود، التداخلات الدوائية)

Table 4 Drug Interactions with BIXLENVO Concomitant Drug Class: Drug Name Effect on Concentration ↑ = Increase, ↓ = Decrease Clinical Comment Antiarrhythmics: digoxin dofetilide ↑ digoxin ↑ dofetilide Use digoxin with caution and monitor digoxin therapeutic concentration. (نشرة بيكتيغرافير وإمتريسيتابين وتينوفوفير ألافيناميد، التداخلات الدوائية)

The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain… (نشرة بيمافانسيرين، التحذيرات والاحتياطات)

…electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment in patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other products that lead to QT prolongation, and those with electrolyte disturbances (e.g., hypokalemia, hypocalcemia, or hypomagnesemia). (نشرة تاكروليموس، التحذيرات والاحتياطات)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (نشرة تحت سترات البزموت وميترونيدازول وتتراسيكلين، التحذيرات والاحتياطات)

…prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine),… (نشرة ترازودون، التحذيرات والاحتياطات)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (نشرة تريبتوريلين، التحذيرات والاحتياطات)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (نشرة فليكاينيد، التداخلات الدوائية)

Agents generally accepted to prolong QT interval include Class 1A (e.g., quinidine, procainamide, disopyramide) and Class III (e.g., amiodarone, sotalol, ibutilide, dofetilide) antiarrhythmics; certain antipsychotics (e.g., thioridazine, haloperidol); certain antidepressants (e.g., venlafaxine, amitriptyline); certain antibiotics (e.g., erythromycin, clarithromycin,… (نشرة توريميفين، التداخلات الدوائية)

Other antiarrhythmics e.g. amiodarone, bepridil, disopyramide, flecainide, lidocaine (systemic), mexiletine, propafenone, quinidine ↑ antiarrhythmics Therapeutic concentration monitoring, if available, is recommended for antiarrhythmics when co-administered with PREZISTA/ritonavir. digoxin ↑ digoxin The lowest dose of digoxin should initially be prescribed. (نشرة دارونافير، التداخلات الدوائية)

Other antiarrhythmics e.g. amiodarone, disopyramide, flecainide, lidocaine (systemic), mexiletine, propafenone, quinidine ↑ antiarrhythmics Clinical monitoring is recommended upon co-administration with antiarrhythmics. digoxin ↑ digoxin When co-administering with digoxin, titrate the digoxin dose and monitor digoxin concentrations. (نشرة دارونافير وكوبيسيستات، التداخلات الدوائية)

Caution should be taken when darifenacin extended-release tablets is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants ( 7.2 ) (نشرة داريفيناسين، التداخلات الدوائية)

QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (نشرة داساتينيب، التحذيرات والاحتياطات)

…development of prolonged QT syndrome, such as: 1) clinically significant bradycardia (less than 50 bpm), 2) any clinically significant cardiac disease, 3) treatment with Class I and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval (see PRECAUTIONS,… (نشرة دروبيريدول، التحذيرات)

Carefully monitor cardiac rhythm when administering SUPRANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (نشرة ديسفلوران، التحذيرات والاحتياطات)

Other Drugs with Anticholinergic Activity The following agents may increase certain actions or side effects of anticholinergic drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine),… (نشرة ديسيكلومين، التداخلات الدوائية)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (نشرة فليكاينيد، التداخلات الدوائية)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (نشرة فليكاينيد، التداخلات الدوائية)

(See DOSAGE AND ADMINISTRATION ) Drugs that inhibit cytochrome P450IID6, such as quinidine , might increase the plasma concentrations of flecainide in patients that are on chronic flecainide therapy; especially if these patients are extensive metabolizers. (نشرة فليكاينيد، التداخلات الدوائية)

…anesthetics or agents structurally related to amide- type local anesthetics, since the toxic effects of these drugs are additive. [See Drug Interactions 7.0 ] Patients treated with class III antiarrhythmic drugs (e.g., amiodarone) should be under close surveillance and ECG monitoring considered, since cardiac effects may be additive. [See Drug Interactions 7.0… (نشرة روبيفاكايين، التحذيرات والاحتياطات)

QT Interval Prolongation The overall analysis of ECG data in pediatric patients indicates that the concomitant use of Rocuronium Bromide Injection with general anesthetic agents can prolong the QTc interval [see Clinical Studies ( 14.3 )]. (نشرة روكورونيوم، التحذيرات والاحتياطات)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (نشرة فليكاينيد، التداخلات الدوائية)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (نشرة فليكاينيد، التداخلات الدوائية)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (نشرة فليكاينيد، التداخلات الدوائية)

In healthy subjects, 75 mg once daily and 300 mg once daily (3 times and 12 times the dose in EDURANT) have been shown to prolong the QTc interval of the electrocardiogram. (نشرة ريلبيفيرين، التحذيرات والاحتياطات)

Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (نشرة سورافينيب، التحذيرات والاحتياطات)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (نشرة فليكاينيد، التداخلات الدوائية)

Antiarrhythmics: amiodarone Effect on amiodarone, sofosbuvir, velpatasvir, and voxilaprevir concentrations unknown Coadministration of amiodarone with VOSEVI may result in serious symptomatic bradycardia. (نشرة سوفوسبوفير وفيلباتاسفير، التداخلات الدوائية)

Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (نشرة سونيتينيب، التحذيرات والاحتياطات)

Avoid use of Citalopram Capsules in patients with congenital long QT syndrome, bradycardia, hypokalemia or hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure and patients taking other drugs that prolong the QTc interval. (نشرة سيتالوبرام، التحذيرات والاحتياطات)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (نشرة سيفوفلوران، التحذيرات)

In healthy subjects receiving cimetidine (1 gm daily) for one week, plasma flecainide levels increased by about 30% and half-life increased by about 10%. (نشرة فليكاينيد، التداخلات الدوائية)

Dose adjustments may be required for concomitant medications that are predominantly metabolized by CYP2D6 (e.g., desipramine, metoprolol, and carvedilol) and particularly those with a narrow therapeutic index (e.g., flecainide and most tricyclic antidepressants) [see Clinical Pharmacology ( 12.3 )] . (نشرة سيناكالسيت، التداخلات الدوائية)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (نشرة فليكاينيد، التداخلات الدوائية)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (نشرة فليكاينيد، التداخلات الدوائية)

Other Anticholinergic Drugs There is potential for an additive interaction between glycopyrrolate and concomitantly used anticholinergic drugs (e.g., tricyclic antidepressants, anti-epileptics, class I antiarrhythmics, anti­-spasmodics, amantadine) resulting in increased anticholinergic adverse reactions. (نشرة غليكوبيرولات، التداخلات الدوائية)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (نشرة غوسيريلين، التحذيرات والاحتياطات)

Use with caution in combination with other drugs that prolong the QT interval ( 4.2 , 5.11 , 7.7 , 7.8 ) 7.1 Monoamine Oxidase Inhibitors (MAOI) [See Dosage and Administration ( 2.9 , 2.10 ), Contraindications ( 4.1 ), and Warnings and Precautions ( 5.2 )] . (نشرة فلوكسيتين، التداخلات الدوائية)

…as: 1) clinically significant bradycardia (less than 50 bpm), 2) any clinically significant cardiac disease, including baseline prolonged QT interval, 3) treatment with Class 1 and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval and 6) electrolyte… (نشرة فنتانيل، التحذيرات والاحتياطات)

…Antidepressants, QTc Prolonging Drugs Formoterol, as with other beta 2 -agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the effect of adrenergic agonists on the cardiovascular system may be potentiated by these agents. (نشرة فورموتيرول، التداخلات الدوائية)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (نشرة فليكاينيد، التداخلات الدوائية)

Because both of these drugs have negative inotropic properties and the effects of coadministration with flecainide acetate are unknown, neither disopyramide nor verapamil should be administered concurrently with flecainide acetate unless, in the judgment of the physician, the benefits of this combination outweigh the risks. (نشرة فليكاينيد، التداخلات الدوائية)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (نشرة فليكاينيد، التداخلات الدوائية)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (نشرة فليكاينيد، التداخلات الدوائية)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (نشرة فليكاينيد، التداخلات الدوائية)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (نشرة فليكاينيد، التداخلات الدوائية)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (نشرة فليكاينيد، التداخلات الدوائية)

…droperidol, pimozide), specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin), Class 1A antiarrhythmic medications (e.g., quinidine, procainamide) or Class III antiarrhythmics (e.g., amiodarone, sotalol), and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, probucol or tacrolimus). (نشرة كلوزابين، التحذيرات والاحتياطات)

…Class 1A antiarrythmics (e.g., quinidine, procainamide) or Class III antiarrythmics (e.g., amiodarone, sotalol), antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to prolong the QTc interval (e.g., pentamidine, levomethadyl acetate, methadone). (نشرة كويتيابين، التحذيرات والاحتياطات)

Antiarrhythmics disopyramide, dofetilide, dronedarone, quinidine digoxin Disopyramide, dofetilide, dronedarone, quinidine: The potential increase in plasma concentrations of these drugs when coadministered with ketoconazole may increase the risk of serious cardiovascular events including QT prolongation. (نشرة كيتوكونازول، التداخلات الدوائية)

…disease and preexisting conduction system abnormalities, elderly patients with sick sinus syndrome, patients with atrial fibrillation with slow ventricular response, patients with myocardial ischemia or patients receiving drugs known to prolong the PR interval (e.g. verapamil) or QRS interval (e.g. flecainide or quinidine) [see CLINICAL PHARMACOLOGY ( 12.2 )] . (نشرة كينين، التحذيرات والاحتياطات)

…combination with others drugs or herbal products that are known to prolong the QT interval, including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmics, antipsychotics (e.g., chlorpromazine, haloperidol, thioridazine, ziprasidone), antibiotics (e.g., moxifloxacin), or any other drug known to prolong the QT interval… (نشرة لوبيراميد، التحذيرات)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (نشرة فليكاينيد، التداخلات الدوائية)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (نشرة لوفيكسيدين، التحذيرات والاحتياطات)

Antiarrhythmics: amiodarone Effect on amiodarone, ledipasvir, and sofosbuvir concentrations unknown Coadministration of amiodarone with ledipasvir and sofosbuvir may result in serious symptomatic bradycardia. (نشرة ليديباسفير وسوفوسبوفير، التداخلات الدوائية)

Clinical Comment Antiarrhythmics: digoxin ↑ digoxin Use with caution and monitor digoxin therapeutic concentration. (نشرة ليناكابافير، التداخلات الدوائية)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (نشرة ليوبروليد، التحذيرات والاحتياطات)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (نشرة فليكاينيد، التداخلات الدوائية)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (نشرة فليكاينيد، التداخلات الدوائية)

Drugs that Prolong the QT Interval QT prolongation has been reported, particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval. (نشرة ميترونيدازول، التداخلات الدوائية)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (نشرة فليكاينيد، التداخلات الدوائية)

Examples: Drugs known to have potential to prolong QT interval: Class I and III antiarrhythmics, some neuroleptics and tricyclic antidepressants, and calcium channel blockers. (نشرة ميثادون، التداخلات الدوائية)

Other Drugs that Prolong the QTc Interval Coadministration of other drugs known to alter cardiac conduction (e.g., anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H 1 -blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval. (نشرة ميفلوكين، التداخلات الدوائية)

There is little or no experience with high exposure, concomitant dosing with other QT-prolonging drugs, or potassium channel variants resulting in a long QT interval. [See Warnings & Precautions ( 5.6 )] To minimize risk, the lowest effective dose should always be used. (نشرة ميفيبريستون، التحذيرات والاحتياطات)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (نشرة فليكاينيد، التداخلات الدوائية)

Drugs Metabolized by CYP2D6: Bupropion inhibits CYP2D6 and can increase concentrations of antidepressants, (e.g., selective serotonin reuptake inhibitors and many tricyclics), antipsychotics (e.g., haloperidol, risperidone and thioridazine), beta-blockers (e.g., metoprolol) and Type 1C antiarrhythmics (e.g., propafenone and flecainide). (نشرة نالتريكسون وبوبروبيون، التداخلات الدوائية)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (نشرة فليكاينيد، التداخلات الدوائية)

This observation should be considered in making clinical decisions regarding patient monitoring when prescribing HYSINGLA ER in patients with congestive heart failure, bradyarrhythmias, electrolyte abnormalities, or who are taking medications that are known to prolong the QTc interval. (نشرة هيدروكودون، التحذيرات والاحتياطات)

Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (نشرة فليكاينيد، التداخلات الدوائية)

Consequently, interactions with other drugs which are highly protein bound (e.g., anticoagulants ) would not be expected. (نشرة فليكاينيد، التداخلات الدوائية)

Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (نشرة فليكاينيد، التداخلات الدوائية)

Consequently, interactions with other drugs which are highly protein bound (e.g., anticoagulants ) would not be expected. (نشرة فليكاينيد، التداخلات الدوائية)

Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (نشرة فليكاينيد، التداخلات الدوائية)

The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine, cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). (نشرة أموكسابين، التداخلات الدوائية)

The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). (نشرة أميتريبتيلين، التداخلات الدوائية)

Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (نشرة فليكاينيد، التداخلات الدوائية)

Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (نشرة فليكاينيد، التداخلات الدوائية)

Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (نشرة فليكاينيد، التداخلات الدوائية)

Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (نشرة فليكاينيد، التداخلات الدوائية)

Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (نشرة فليكاينيد، التداخلات الدوائية)

WARNINGS Proarrhythmia: Like other antiarrhythmic agents, CORVERT Injection can induce or worsen ventricular arrhythmias in some patients. (نشرة إيبوتيليد، التحذيرات)

Consequently, interactions with other drugs which are highly protein bound (e.g., anticoagulants ) would not be expected. (نشرة فليكاينيد، التداخلات الدوائية)

The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). (نشرة إيميبرامين، التداخلات الدوائية)

Consequently, interactions with other drugs which are highly protein bound (e.g., anticoagulants ) would not be expected. (نشرة فليكاينيد، التداخلات الدوائية)

Examples propafenone, flecainide, atomoxetine, desipramine, dextromethorphan, metoprolol, nebivolol, perphenazine, tolterodine, venlafaxine, risperidone. (نشرة باروكسيتين، التداخلات الدوائية)

…chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout–allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol (see WARNINGS however), and quinidine; and (6) analgesics, antipyretics and anti-inflammatories–propoxyphene, aspirin, indomethacin, and phenylbutazone. (نشرة برازوسين، التداخلات الدوائية)

The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics, propafenone and flecainide). (نشرة بروتريبتيلين، الاحتياطات)

Pentoxifylline extended-release tablets have been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, and antiarrhythmics, without observed problems. (نشرة بنتوكسيفيلين، التداخلات الدوائية)

Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (نشرة فليكاينيد، التداخلات الدوائية)

Drug Interactions Metabolism of a number of medications, including antipsychotics, antidepressants, β-blockers, and antiarrhythmics, occurs through the cytochrome P450 2D6 isoenzyme (debrisoquine hydroxylase). (نشرة بيرفينازين، التداخلات الدوائية)

Aminoglycoside antibiotics, local and some general anesthetics, antiarrhythmic agents, and other drugs that interfere with neuromuscular transmission should be used cautiously, if at all. (نشرة بيريدوستيغمين، التداخلات الدوائية)

Consequently, interactions with other drugs which are highly protein bound (e.g., anticoagulants ) would not be expected. (نشرة فليكاينيد، التداخلات الدوائية)

Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (نشرة فليكاينيد، التداخلات الدوائية)

Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (نشرة فليكاينيد، التداخلات الدوائية)

Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (نشرة فليكاينيد، التداخلات الدوائية)

The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). (نشرة تريميبرامين، التداخلات الدوائية)

Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (نشرة فليكاينيد، التداخلات الدوائية)

Drugs predominantly metabolized by the CYP450 2D6 isozyme include the following drug classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone) and monoamine oxidase inhibitors Type B. (نشرة تيربينافين، التداخلات الدوائية)

Moderate or Weak CYP1A2 Inhibitors Concomitant use of Zanaflex with moderate or weak CYP1A2 inhibitors (e.g., zileuton, antiarrhythmics [amiodarone, mexiletine, propafenone, and verapamil], cimetidine, famotidine, oral contraceptives, acyclovir, and ticlopidine) should be avoided. (نشرة تيزانيدين، التداخلات الدوائية)

Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (نشرة فليكاينيد، التداخلات الدوائية)

Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (نشرة فليكاينيد، التداخلات الدوائية)

Consequently, interactions with other drugs which are highly protein bound (e.g., anticoagulants ) would not be expected. (نشرة فليكاينيد، التداخلات الدوائية)

The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type IC antiarrhythmics propafenone and flecainide). (نشرة ديسيبرامين، التداخلات الدوائية)

There has been too little experience with the coadministration of flecainide acetate with nifedipine or diltiazem to recommend concomitant use. (نشرة فليكاينيد، التداخلات الدوائية)

Consequently, interactions with other drugs which are highly protein bound (e.g., anticoagulants ) would not be expected. (نشرة فليكاينيد، التداخلات الدوائية)

Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (نشرة فليكاينيد، التداخلات الدوائية)

Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (نشرة فليكاينيد، التداخلات الدوائية)

Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (نشرة فليكاينيد، التداخلات الدوائية)

Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (نشرة فليكاينيد، التداخلات الدوائية)

Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (نشرة فليكاينيد، التداخلات الدوائية)

Consequently, interactions with other drugs which are highly protein bound (e.g., anticoagulants ) would not be expected. (نشرة فليكاينيد، التداخلات الدوائية)

Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (نشرة فليكاينيد، التداخلات الدوائية)

Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (نشرة فليكاينيد، التداخلات الدوائية)

Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (نشرة فليكاينيد، التداخلات الدوائية)

The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). (نشرة كلوميبرامين، التداخلات الدوائية)

Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (نشرة فليكاينيد، التداخلات الدوائية)

Cardiac Rhythm and Conduction Abnormalities In vitro testing showed that lamotrigine exhibits Class IB antiarrhythmic activity at therapeutically relevant concentrations [see Clinical Pharmacology ( 12.2 )] . (نشرة لاموتريجين، التحذيرات والاحتياطات)

Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (نشرة فليكاينيد، التداخلات الدوائية)

Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (نشرة فليكاينيد، التداخلات الدوائية)

Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (نشرة فليكاينيد، التداخلات الدوائية)

…for Drug Interaction: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. (نشرة ميدودرين، الاحتياطات)

The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). (نشرة نورتريبتيلين، التداخلات الدوائية)

There has been too little experience with the coadministration of flecainide acetate with nifedipine or diltiazem to recommend concomitant use. (نشرة فليكاينيد، التداخلات الدوائية)

Examples include (but are not limited to): Class 1A antiarrhythmics (e.g., procainamide, quinidine, disopyramide); Class 3 antiarrhythmics (e.g., amiodarone, sotalol); and other drugs such as citalopram, erythromycin, levofloxacin, methadone, and ziprasidone. (نشرة هالوبيريدول، التداخلات الدوائية)

Consequently, interactions with other drugs which are highly protein bound (e.g., anticoagulants ) would not be expected. (نشرة فليكاينيد، التداخلات الدوائية)

These include Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmics, certain antipsychotics (e.g., ziprasidone, iloperidone, clozapine, quetiapine, chlorpromazine), certain antidepressants (e.g., citalopram, fluoxetine), certain antibiotics (e.g., azithromycin, erythromycin, clarithromycin, gatifloxacin, moxifloxacin);… (نشرة هيدروكسيزين، الاحتياطات)

Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (نشرة فليكاينيد، التداخلات الدوائية)

Consequently, interactions with other drugs which are highly protein bound (e.g., anticoagulants ) would not be expected. (نشرة فليكاينيد، التداخلات الدوائية)